Clene Nanomedicine Announces First Patients Enrolled in HEALEY ALS Platform Trial

SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, is very pleased that the Sean M Healey & AMG Center for ALS at Mass General announced the first patients have been enrolled into the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS (NEALS) consortium. Clene Nanomedicine's lead drug candidate, CNM-Au8, is a first-of-its-kind therapeutic nanocatalyst with demonstrated neuroprotective and remyelinating properties in preclinical models. CNM-Au8 was selected as one of the first drug regimens to be evaluated as an ALS treatment in the HEALEY ALS Platform Trial by a panel of expert amyotrophic lateral sclerosis (ALS) scientists. This breakthrough trial, the first ever platform trial for the treatment of ALS, is designed to reduce trial time, reduce costs and increase patient participation in developing novel therapies for ALS. The trial includes substantial financial support from philanthropic donors and foundations, and provides access to 54 expert ALS clinical trial sites across the United States from the NEALS consortium."We are excited that the HEALEY ALS Platform Trial has begun enrollment of patients, and that the dosing of CNM-Au8, as one of the first three therapies chosen, will begin imminently," said Rob Etherington, President and CEO of Clene. "This trial will be key in our mission of finding solutions to the progressive neurologic impairment of ALS, in order to aid those suffering from this deadly neurodegenerative disease."Robert Glanzman, MD, FAAN, Clene's Chief Medical Officer,Afurther commented, "We at Clene are very excited to be partnering with the Healey Center for ALS at Mass General in this critically important effort. The announcement of first patients enrolled is the culmination of a lot of hard work by a large collaborative team, led by the Healey Center.""This is a huge milestone for the ALS community and beyond, and the team here at the Healey Center is eager and excited to begin enrolling patients in the first-ever platform trial for this disease," saysAMerit Cudkowicz, MD, director of the Sean M. Healey & AMG Center for ALS and chief of Neurology at MGH. "We're grateful to our supporters and collaborators who have worked tirelessly throughout this pandemic to ensure the trial can begin safely and efficiently."
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »